Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
|Articles|March 8, 2022
Daily Medication Pearl: Empagliflozin and Linagliptin (Glyxambi)
Author(s)Saro Arakelians, PharmD
Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Advertisement
Indication: Empagliflozin and linagliptin (Glyxambi)is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.
Insight:
- Dosing: The recommended dose of Glyxambi is 10 mg empagliflozin/5 mg linagliptin once daily, taken in the morning, with or without food.
- Dosage forms: 10 mg empagliflozin/5 mg linagliptin, 25 mg empagliflozin/5 mg linagliptin
- Adverse events: The most common adverse reactions associated with Glyxambi (a 5% or greater incidence) were urinary tract infections, nasopharyngitis, and upper respiratory tract infections.
- Mechanism of action: Glyxambi combines 2 antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: empagliflozin, a SGLT2 inhibitor, and linagliptin, a dipeptidyl peptidase-4 DPP-4 inhibitor.
- Manufacturer: Boehringer Ingelheim
Sources:
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Tec-Dara Cuts Death Risk 78% Without Raising Fatal Toxicity
5